Search research articles
Contact Us
Filters
Showing results (101-110 of 116) with videos related to
Page
of 12
Sort By:
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America
|
December 10, 1999
Association of primary Pneumocystis carinii infection and sudden infant death syndrome
S L Vargas, C A Ponce, W T Hughes, et al.
Eclinicalmedicine
|
August 8, 2024
Sustained improvements in patient-reported outcomes after long-term sutimlimab in patients with cold agglutinin disease: results from the CADENZA study open-label extension
Alexander Röth, Catherine M Broome, Wilma Barcellini, et al.
Frontiers in Cell and Developmental Biology
|
July 14, 2020
Focused Ultrasound Stimulates ER Localized Mechanosensitive PANNEXIN-1 to Mediate Intracellular Calcium Release in Invasive Cancer Cells
Nan Sook Lee, Chi Woo Yoon, Qing Wang, et al.
Haematologica
|
February 17, 2022
Complement C1s inhibition with sutimlimab results in durable response in cold agglutinin disease: CARDINAL study 1-year interim follow-up results
Alexander Roth, Wilma Barcellini, Shirley D'Sa, et al.
Journal of the American Chemical Society
|
June 4, 2020
Effects of Noncovalent Interactions on High-Spin Fe(IV)-Oxido Complexes
Victoria F Oswald, Justin L Lee, Saborni Biswas, et al.
The New England Journal of Medicine
|
September 10, 2015
Eculizumab in Pregnant Patients with Paroxysmal Nocturnal Hemoglobinuria
Richard J Kelly, Britta Höchsmann, Jeff Szer, et al.
American Journal of Hematology
|
May 29, 2023
Sustained inhibition of complement C1s with sutimlimab over 2 years in patients with cold agglutinin disease
Alexander Röth, Wilma Barcellini, Shirley D'Sa, et al.
Blood
|
June 10, 2022
Sutimlimab in patients with cold agglutinin disease: results of the randomized placebo-controlled phase 3 CADENZA trial
Alexander Röth, Sigbjørn Berentsen, Wilma Barcellini, et al.
The Lancet. Haematology
|
September 2, 2022
Pegcetacoplan versus eculizumab in patients with paroxysmal nocturnal haemoglobinuria (PEGASUS): 48-week follow-up of a randomised, open-label, phase 3, active-comparator, controlled trial
Régis Peffault de Latour, Jeff Szer, Ilene C Weitz, et al.
Eclinicalmedicine
|
August 2, 2024
Long-term efficacy and safety of continued complement C1s inhibition with sutimlimab in cold agglutinin disease: CADENZA study Part B
Alexander Röth, Sigbjørn Berentsen, Wilma Barcellini, et al.
Page
of 12
Search research articles
Search
Showing results (101-110 of 116) with videos related to
Sort By:
Page
of 12
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America
|
December 10, 1999
Association of primary Pneumocystis carinii infection and sudden infant death syndrome
S L Vargas, C A Ponce, W T Hughes, et al.
Eclinicalmedicine
|
August 8, 2024
Sustained improvements in patient-reported outcomes after long-term sutimlimab in patients with cold agglutinin disease: results from the CADENZA study open-label extension
Alexander Röth, Catherine M Broome, Wilma Barcellini, et al.
Frontiers in Cell and Developmental Biology
|
July 14, 2020
Focused Ultrasound Stimulates ER Localized Mechanosensitive PANNEXIN-1 to Mediate Intracellular Calcium Release in Invasive Cancer Cells
Nan Sook Lee, Chi Woo Yoon, Qing Wang, et al.
Haematologica
|
February 17, 2022
Complement C1s inhibition with sutimlimab results in durable response in cold agglutinin disease: CARDINAL study 1-year interim follow-up results
Alexander Roth, Wilma Barcellini, Shirley D'Sa, et al.
Journal of the American Chemical Society
|
June 4, 2020
Effects of Noncovalent Interactions on High-Spin Fe(IV)-Oxido Complexes
Victoria F Oswald, Justin L Lee, Saborni Biswas, et al.
The New England Journal of Medicine
|
September 10, 2015
Eculizumab in Pregnant Patients with Paroxysmal Nocturnal Hemoglobinuria
Richard J Kelly, Britta Höchsmann, Jeff Szer, et al.
American Journal of Hematology
|
May 29, 2023
Sustained inhibition of complement C1s with sutimlimab over 2 years in patients with cold agglutinin disease
Alexander Röth, Wilma Barcellini, Shirley D'Sa, et al.
Blood
|
June 10, 2022
Sutimlimab in patients with cold agglutinin disease: results of the randomized placebo-controlled phase 3 CADENZA trial
Alexander Röth, Sigbjørn Berentsen, Wilma Barcellini, et al.
The Lancet. Haematology
|
September 2, 2022
Pegcetacoplan versus eculizumab in patients with paroxysmal nocturnal haemoglobinuria (PEGASUS): 48-week follow-up of a randomised, open-label, phase 3, active-comparator, controlled trial
Régis Peffault de Latour, Jeff Szer, Ilene C Weitz, et al.
Eclinicalmedicine
|
August 2, 2024
Long-term efficacy and safety of continued complement C1s inhibition with sutimlimab in cold agglutinin disease: CADENZA study Part B
Alexander Röth, Sigbjørn Berentsen, Wilma Barcellini, et al.
Page
of 12